Bonini S, Schiavone M, Bonini S, Magrini L, Lischetti P, Lambiase A, Bucci M G
Department of Opthalmology, University of Rome Tor Vergata, Italy.
Ophthalmology. 1997 May;104(5):849-53. doi: 10.1016/s0161-6420(97)30223-1.
The purpose of the study is to evaluate in a double-blind, randomized study the efficacy of lodoxamide tromethamine 0.1% versus placebo.
Signs and symptoms, tear tryptase, and tear fluid cytology were evaluated in 20 asymptomatic subjects with allergic conjunctivitis. The study included three allergen challenges in skin test-positive patients. At the first visit, a threshold dose of allergen was established. At the second visit, a bilateral ocular challenge was performed without pretreatment. At the third visit, either lodoxamide or placebo eye drops were used for 1 week before ocular challenge.
Lodoxamide significantly reduced tryptase levels (P < 0.01), neutrophils (P < 0.04), and eosinophils (P < 0.01) in the tear fluid and significantly inhibited ocular itching (P < 0.02) when compared with that of placebo.
Lodoxamide is effective in reducing tryptase levels and the recruitment of inflammatory cells in the tear fluid after allergen challenge.
本研究旨在通过双盲随机研究评估0.1%的氨来呫诺 tromethamine与安慰剂的疗效。
对20名无症状过敏性结膜炎患者的体征和症状、泪液类胰蛋白酶以及泪液细胞学进行评估。该研究包括对皮肤试验呈阳性的患者进行三次过敏原激发试验。在首次就诊时，确定过敏原的阈剂量。在第二次就诊时，未经预处理进行双侧眼部激发试验。在第三次就诊时，在眼部激发试验前1周使用氨来呫诺或安慰剂眼药水。
与安慰剂相比，氨来呫诺显著降低了泪液中的类胰蛋白酶水平（P < 0.01）、中性粒细胞（P < 0.04）和嗜酸性粒细胞（P < 0.01），并显著抑制了眼部瘙痒（P < 0.02）。
氨来呫诺在过敏原激发后可有效降低泪液中的类胰蛋白酶水平并减少炎症细胞的募集。
